Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology
- PMID: 39482471
- PMCID: PMC11950336
- DOI: 10.1038/s41401-024-01404-7
Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology
Abstract
Poria cocos and its surface layer of Poria cocos (Schw.) Wolf (Polyporaceae), are used in traditional Chinese medicine for its diuretic and renoprotective effects. Phytochemical studies have shown that lanostane and 3,4-seco-lanostane tetracyclic triterpenoids are the main components of P. cocos and its surface layer. Accumulating evidence shows that triterpenoid components in P. cocos and its surface layer contribute to their renoprotective effect. The surface layer of P. cocos showed a stronger diuretic effect than P. cocos. The ethanol extract of the surface layer and its components improved acute kidney injury, acute kidney injury-to-chronic kidney disease transition and chronic kidney disease such as diabetic kidney disease, nephrotic syndrome and tubulointerstitial nephropathy, and protected against renal fibrosis. It has been elucidated that P. cocos and its surface layer exert a diuretic effect and improve kidney diseases through a variety of molecular mechanisms such as aberrant pathways TGF-β1/Smad, Wnt/β-catenin, IκB/NF-κB and Keap1/Nrf2 signaling as well as the activation of renin-angiotensin system, matrix metalloproteinases, aryl hydrocarbon receptor and endogenous metabolites. These studies further confirm the renoprotective effect of P. cocos and its surface layer and provide a beneficial basis to its clinical use in traditional medicine.
Keywords: Poria cocos; TGF-β1/Smad; acute kidney injury; chronic kidney disease; renal fibrosis; renoprotective effect.
© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
References
-
- Rios JL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 2011;77:681–91. - PubMed
-
- Wang YZ, Zhang J, Zhao YL, Li T, Shen T, Li JQ, et al. Mycology, cultivation, traditional uses, phytochemistry and pharmacology of Wolfiporia cocos (Schwein.) Ryvarden et Gilb.: a review. J Ethnopharmacol. 2013;147:265–76. - PubMed
-
- Chen L, Cao G, Wang M, Feng YL, Chen DQ, Vaziri ND, et al. The matrix metalloproteinase-13 inhibitor poricoic acid ZI ameliorates renal fibrosis by mitigating epithelial-mesenchymal transition. Mol Nutr Food Res. 2019;63:e1900132. - PubMed
-
- Zhao YY, Feng YL, Bai X, Tan XJ, Lin RC, Mei Q. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PLoS One. 2013;8:e59617. - PMC - PubMed
-
- Kobira S, Atsumi T, Kakiuchi N, Mikage M. Difference in cultivation characteristics and genetic polymorphism between Chinese and Japanese strains of Wolfiporia cocos Ryvarden et Gilbertson (Poria cocos Wolf). J Nat Med. 2012;66:493–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
